文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[镓]Ga-PSMA-11 PET/CT图像解读在新诊断前列腺癌男性患者中的观察者间一致性。

Interobserver agreement of [Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer.

作者信息

Derwael Céline, Lavergne Olivier, Lovinfosse Pierre, Nechifor Vlad, Salvé Mallory, Waltregny David, Hustinx Roland, Withofs Nadia

机构信息

Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Avenue de l'Hôpital, 1, 4000, Liege, Belgium.

Department of Urology, CHR of Liege, Liege, Belgium.

出版信息

EJNMMI Res. 2020 Feb 28;10(1):15. doi: 10.1186/s13550-020-0596-4.


DOI:10.1186/s13550-020-0596-4
PMID:32112230
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7048889/
Abstract

BACKGROUND: Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aimed at retrospectively evaluating interobserver agreement of [Ga]Ga-PSMA-11 PET/CT images interpretation according to PC molecular imaging standardized evaluation (PROMISE) criteria and reproducibility of PSMA reporting and data systems (RADS). METHODS: Forty-three patients with newly diagnosed, histologically proven intermediate- or high-risk PC, eligible for radical prostatectomy and who underwent [Ga]Ga-PSMA-11 PET/CT before surgery were retrospectively included. Three nuclear medicine physicians (2 experienced and 1 resident) independently reviewed PET/CT images. Interpretation of [Ga]Ga-PSMA-11 PET/CT images was based on PROMISE criteria including miTNM staging and lesions miPSMA expression score visual estimation and PSMA-RADS version 1.0 for a given scan. Readers' agreement was measured using Krippendorff's coefficients RESULTS: Agreement between observers was almost perfect (coefficient ≥ 0.81) for miM; it was substantial (coefficient ≥ 0.61) for the following criteria: miT, miN, PSMA-RADS, and miPSMA expression score of primary PC lesion and metastases. However, agreement was moderate (coefficient = 0.41-0.60) for miPSMA score of positive lymph nodes and for detection of PC primary lesion. CONCLUSION: Visual interpretation of [Ga]Ga-PSMA-11 PET/CT images in patients with newly diagnosed PC in a clinical setting leads to at least substantial agreement for PROMISE criteria and PSMA-RADS classification except for PC primary lesion detection and for miPSMA expression scoring of positive lymph nodes that might have been hampered by the interindividual variability of reference organs PSMA expression.

摘要

背景:前列腺特异性膜抗原(PSMA)配体PET/CT在前列腺癌(PC)成像中已取得了有前景的结果,但仍缺乏简单且可重复的报告标准。本研究旨在根据PC分子成像标准化评估(PROMISE)标准回顾性评估[镓]镓-PSMA-11 PET/CT图像解读的观察者间一致性以及PSMA报告和数据系统(RADS)的可重复性。 方法:回顾性纳入43例新诊断的、经组织学证实为中高危PC且适合行根治性前列腺切除术并在手术前行[镓]镓-PSMA-11 PET/CT检查的患者。三名核医学医师(2名经验丰富的和1名住院医师)独立阅片。[镓]镓-PSMA-11 PET/CT图像解读基于PROMISE标准,包括miTNM分期和病变miPSMA表达评分视觉估计以及针对给定扫描的PSMA-RADS 1.0版标准。使用Krippendorff系数测量读者间的一致性。结果:观察者间对于miM的一致性几乎为完美(系数≥0.81);对于以下标准,一致性为实质性(系数≥0.61):miT、miN、PSMA-RADS以及原发性PC病变和转移灶的miPSMA表达评分。然而,对于阳性淋巴结的miPSMA评分以及PC原发性病变的检测,一致性为中等(系数 = 0.41 - 0.60)。 结论:在临床环境中,对新诊断PC患者的[镓]镓-PSMA-11 PET/CT图像进行视觉解读,除了PC原发性病变检测以及阳性淋巴结的miPSMA表达评分可能因参考器官PSMA表达的个体间变异性而受到影响外,对于PROMISE标准和PSMA-RADS分类至少达成了实质性一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/c9fd5c6d195e/13550_2020_596_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/097919c1f38e/13550_2020_596_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/dcd0bdbb19f6/13550_2020_596_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/1eb71163df18/13550_2020_596_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/c9fd5c6d195e/13550_2020_596_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/097919c1f38e/13550_2020_596_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/dcd0bdbb19f6/13550_2020_596_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/1eb71163df18/13550_2020_596_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda5/7048889/c9fd5c6d195e/13550_2020_596_Fig4_HTML.jpg

相似文献

[1]
Interobserver agreement of [Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer.

EJNMMI Res. 2020-2-28

[2]
Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria.

Nucl Med Commun. 2020-8

[3]
Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.

Abdom Radiol (NY). 2019-7

[4]
Comparison of 3 Interpretation Criteria for Ga-PSMA11 PET Based on Inter- and Intrareader Agreement.

J Nucl Med. 2019-9-27

[5]
Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups.

Nucl Med Commun. 2022-1-1

[6]
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging.

J Nucl Med. 2018-9-6

[7]
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.

Hell J Nucl Med. 2019

[8]
Interobserver and intraobserver agreement in PET/CT with [F]DCFPyL according to TNM molecular and PSMA-RADS 2.0 criteria.

Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024

[9]
High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data.

Clin Nucl Med. 2023-3-1

[10]
The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0.

EJNMMI Res. 2021-1-6

引用本文的文献

[1]
Interobserver and intraobserver agreement for equivocal lesions in Ga-68 PSMA PET/CT according to PSMA-RADS 2.0 criteria.

Ann Nucl Med. 2025-9-10

[2]
A fully automated AI-based method for tumour detection and quantification on [F]PSMA-1007 PET-CT images in prostate cancer.

EJNMMI Phys. 2025-8-20

[3]
Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.

Radiol Imaging Cancer. 2025-5

[4]
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study.

BMC Med Imaging. 2025-1-20

[5]
The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer.

EJNMMI Res. 2024-10-24

[6]
Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients.

Sci Rep. 2024-7-5

[7]
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.

Eur Urol. 2023-11

[8]
A VISION Substudy of Reader Agreement on Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for Lu-PSMA-617 Radioligand Therapy.

J Nucl Med. 2023-8

[9]
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians.

Eur J Nucl Med Mol Imaging. 2022-8

[10]
Using Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice.

J Nucl Med. 2022-12

本文引用的文献

[1]
Comparison of 3 Interpretation Criteria for Ga-PSMA11 PET Based on Inter- and Intrareader Agreement.

J Nucl Med. 2019-9-27

[2]
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).

Eur J Nucl Med Mol Imaging. 2019-8-22

[3]
Editorial: assessment of Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!

Transl Androl Urol. 2019-7

[4]
F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Lancet Oncol. 2019-7-30

[5]
Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.

J Nucl Med. 2019-7-13

[6]
Detection and localisation of primary prostate cancer using gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.

BJU Int. 2020-7

[7]
Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.

Abdom Radiol (NY). 2019-7

[8]
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

JAMA Oncol. 2019-6-1

[9]
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using Ga-PSMA11 PET/CT.

J Nucl Med. 2019-3-8

[10]
Combination of Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

J Nucl Med. 2018-12-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索